Dong, Li
Zhang, Rui-Heng
Zhou, Wen-Da
Li, Yi-Fan
Li, He-Yan
Wu, Hao-Tian
Shi, Xu-Han
Jonas, Jost. B.
Wei, Wen-Bin
Article History
Received: 20 January 2022
Accepted: 21 April 2022
First Online: 27 April 2022
Declarations
:
: The Ethics Committee of the Beijing Tongren Hospital study approved the study, which followed the ARVO Statement for the use of animals in ophthalmic and vision research. All methods were performed in accordance with the ARRIVE guidelines. All methods were carried out in accordance with relevant guidelines and regulations.
: All authors agreed for publication of this study
: Not applicable
: Jost B. Jonas: European patent EP 3 271 392, JP 2021–119187, and US 11,008,385: „Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; Patent application: European patent application: PCT/EP2021/058500: Agents for the use in the therapeutic or prophylactic treatment of retinal pigment epithelium associated diseases. All other authors: None.